title: Cardiovascular complications secondary to Graves' disease: a prospective study from Ukraine.
abstract: BACKGROUND
  Graves' disease (GD) is a common cause of hyperthyroidism resulting in development of thyrotoxic heart disease (THD).
  
  
  OBJECTIVE
  to assess cardiovascular disorders and health related quality of life (HRQoL) in patients with THD secondary to GD.
  
  
  METHODS
  All patients diagnosed with THD secondary to GD between January 2011 and December 2013 were eligible for this study. Clinical assessment was performed at baseline and at the follow-up visit after the restoring of euthyroid state. HRQoL was studied with a questionnaire EQ-5D-5L.
  
  
  RESULTS
  Follow-up data were available for 61 patients, but only 30 patients with THD secondary to GD were consented to participate in investigation of their HRQoL. The frequency of cardiovascular complications was significantly reduced as compared before and after the antithyroid therapy as follows: resting heart rate (122 vs. 74 bpm), blood pressure: systolic (155 vs. 123 mm Hg), diastolic (83 vs. 66 mm Hg), supraventricular premature contractions (71% vs. 7%), atrial fibrillation (72% vs. 25%), congestive heart failure (69% vs. 20%), thyrotoxic cardiomyopathy (77% vs. 26%), all p<0.01. Anti-TSH receptor antibodies were determined as independent predictor of left ventricular geometry changes, (b-coefficient = 0.04, 95%CI 0.01-0.07, p = 0.02). HRQoL was improved in all domains and self-rated health increased from 43 to 75 units by visual analogue score (p<0.001).
  
  
  CONCLUSIONS
  Restoring of euthyroid state in patients with GD is associated with significant elimination of cardiovascular disorders and improvement of HRQoL. To our knowledge this is the first study evaluating Ukrainian patients with THD secondary to GD with focus on HRQoL.
authors: Department of Therapy, Shupyk National Medical Academy of Postgraduate Education, 04112 Kiev, Ukraine; Department of Functional Diagnostic, Kyiv City Teaching Endocrinological Center, 01034 Kiev, Ukraine.
authors: Iryna
authors: I
authors: Tsymbaliuk
authors: Department of Surgery #4, Bogomolets National Medical University, 01601 Kiev, Ukraine; Department of Oncology-Pathology, Karolinska Institutet, 17176 Stockholm, Sweden.
authors: Dmytro
authors: D
authors: Unukovych
authors: Department of Therapy, Shupyk National Medical Academy of Postgraduate Education, 04112 Kiev, Ukraine; Department of Functional Diagnostic, Kyiv City Teaching Endocrinological Center, 01034 Kiev, Ukraine.
authors: Nataliia
authors: N
authors: Shvets
authors: Department of Surgery #4, Bogomolets National Medical University, 01601 Kiev, Ukraine; Department of Oncology-Pathology, Karolinska Institutet, 17176 Stockholm, Sweden.
authors: Andrii
authors: A
authors: Dinets
mesh_terms: D013956:Antithyroid Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation; D018880:Atrial Premature Complexes; D001794:Blood Pressure; D002318:Cardiovascular Diseases / Q000209:etiology / Q000503:physiopathology*; D006111:Graves Disease / Q000150:complications*; D006333:Heart Failure; D006339:Heart Rate / Q000502:physiology; D006801:Humans; D011446:Prospective Studies; D011788:Quality of Life; D012044:Regression Analysis; D011795:Surveys and Questionnaires; D013971:Thyrotoxicosis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology*; D014455:Ukraine
chemical_list: D013956:Antithyroid Agents